BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Lin C, Kao J. Perspectives and control of hepatitis B virus infection in Taiwan. Journal of the Formosan Medical Association 2015;114:901-9. [DOI: 10.1016/j.jfma.2015.06.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
2 Chen CH, Hsieh HH, Wu TY. Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan. J Oncol Pharm Pract 2021;27:63-70. [PMID: 32264743 DOI: 10.1177/1078155220913095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Yang CX, Lai WJ, Tang YM. Progress in prevention and treatment of HBV reactivation associated with chemotherapy in malignant tumor patients. Shijie Huaren Xiaohua Zazhi 2016; 24(7): 1048-1053 [DOI: 10.11569/wcjd.v24.i7.1048] [Reference Citation Analysis]
4 Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1528-34. [PMID: 22497450 DOI: 10.1111/j.1440-1746.2012.07145.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
5 Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Devel Ther. 2013;8:13-24. [PMID: 24376343 DOI: 10.2147/dddt.s41423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kim HK, Kang W, Sinn DH, Lee JH, Kim WS, Kim SJ. Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. Korean J Intern Med 2020;35:194-204. [PMID: 30935195 DOI: 10.3904/kjim.2018.196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ruan J, Sun S, Cheng X, Han P, Zhang Y, Sun D. Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro. Virol J 2020;17:89. [PMID: 32611423 DOI: 10.1186/s12985-020-01339-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Sun WC, Hsu PI, Yu HC, Lin KH, Tsay FW, Wang HM, Tsai TJ, Chen WC, Lai KH, Cheng JS. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLoS One. 2015;10:e0116978. [PMID: 25658926 DOI: 10.1371/journal.pone.0116978] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
9 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 21.8] [Reference Citation Analysis]
10 Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013;2013:259148. [PMID: 23533738 DOI: 10.1155/2013/259148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
11 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
12 Pawlowska M, Domagalski K. Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12317] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43 [DOI: 10.5315/wjh.v3.i2.29] [Reference Citation Analysis]
14 Liu S, Peng N, Xie J, Hao Q, Zhang M, Zhang Y, Xia Z, Xu G, Zhao F, Wang Q, Han T, Zhu Y. Human hepatitis B virus surface and e antigens inhibit major vault protein signaling in interferon induction pathways. Journal of Hepatology 2015;62:1015-23. [DOI: 10.1016/j.jhep.2014.11.035] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
15 Morikawa K, Shimazaki T, Takeda R, Izumi T, Umumura M, Sakamoto N. Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection. Ann Transl Med 2016;4:337. [PMID: 27761441 DOI: 10.21037/atm.2016.08.54] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
16 Xu J, Zhu H, Zhao Y, Wang X, Shen Y, Wang W, Xu F. Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncol Lett 2012;4:471-6. [PMID: 22970045 DOI: 10.3892/ol.2012.745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, Goto H, Hirooka Y. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9:252-256. [PMID: 27329484 DOI: 10.1007/s12328-016-0657-410.1007/s12328-016-0657-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
19 Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study. World J Gastroenterol 2013; 19(6): 923-930 [PMID: 23429298 DOI: 10.3748/wjg.v19.i6.923] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
20 Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, He M, Zhang B, Zhao M. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol 2020;10:582504. [PMID: 33614477 DOI: 10.3389/fonc.2020.582504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Federico A, Brancaccio G, Dallio M, Iodice P, Fabozzi A, Del Prete S, Ciardiello F, Loguercio C, Gaeta GB. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? Dig Liver Dis 2017;49:197-201. [PMID: 27899262 DOI: 10.1016/j.dld.2016.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394 [PMID: 27004086 DOI: 10.4254/wjh.v8.i8.385] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
24 Zhang YQ, Guo JS. Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3860-3866 [PMID: 25852270 DOI: 10.3748/wjg.v21.i13.3860] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
25 Lin CL, Kao JH. Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace. Hepatol Int 2017;11:31-3. [PMID: 28058576 DOI: 10.1007/s12072-016-9782-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Xu L, Tu Z, Xu G, Hu JL, Cai XF, Zhan XX, Wang YW, Huang Y, Chen J, Huang AL. S-phase arrest after vincristine treatment may promote hepatitis B virus replication. World J Gastroenterol 2015; 21(5): 1498-1509 [PMID: 25663769 DOI: 10.3748/wjg.v21.i5.1498] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Nishimura D, Goto H, Hirooka Y. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol 2016;9:252-6. [DOI: 10.1007/s12328-016-0657-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
28 Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PMID: 29968197 DOI: 10.1007/s40261-018-0671-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
29 Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, Gong C. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. J Viral Hepat 2017;24:561-72. [PMID: 28072494 DOI: 10.1111/jvh.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
30 Tseng CM, Chen TB, Hsu YC, Chang CY, Lin JT, Mo LR. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol 2016;12:421-9. [PMID: 27435683 DOI: 10.1111/ajco.12520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
31 Lee RS, Bell CM, Singh JM, Hicks LK. Hepatitis B screening before chemotherapy: a survey of practitioners' knowledge, beliefs, and screening practices. J Oncol Pract 2012;8:325-8, 1 p following 328. [PMID: 23598840 DOI: 10.1200/JOP.2012.000597] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
32 Lei T, Tan F, Hou Z, Liu P, Zhao X, Liu H. Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib. Front Oncol 2020;10:596500. [PMID: 33552970 DOI: 10.3389/fonc.2020.596500] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Tachi Y, Ishikawa T, Katano Y, Yoshioka K, Toyoda H, Kumada T, Goto H, Hirooka Y. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. J Gastroenterol 2016;51:1081-9. [PMID: 26943169 DOI: 10.1007/s00535-016-1187-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
34 Chang WY, Chiu YC, Chiu FW, Hsu YC, Tseng TC, Cheng PN, Yang SS, Liu CJ, Su TH, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. J Infect Dis 2020;222:1345-52. [PMID: 32396638 DOI: 10.1093/infdis/jiaa256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Pandey A, Ezemenari S, Liaukovich M, Richard I, Boris A. A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B. Case Rep Oncol Med. 2018;2018:5985131. [PMID: 30416833 DOI: 10.1155/2018/5985131] [Cited by in Crossref: 9] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
36 Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
37 Jaroszewicz J, Pawłowska M, Simon K, Zarębska-Michaluk D, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Paluch K, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Flisiak R. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther 2020;18:1045-54. [PMID: 32538232 DOI: 10.1080/14787210.2020.1782189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Skupsky J, Hu K. Current hepatitis B treatment guidelines and future research directions. Front Med 2014;8:145-57. [DOI: 10.1007/s11684-014-0335-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
40 Yu LH, Li N, Shi J, Guo WX, Wu MC, Cheng SQ. Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy? Ann Surg Oncol. 2014;21:1010-1015. [PMID: 24121884 DOI: 10.1245/s10434-013-3320-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]